I see, goo_老虎社区_美港股上老虎

new_money
2021-10-14

I see, good

Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday

New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.

Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":825232679,"tweetId":"825232679","gmtCreate":1634226272357,"gmtModify":1634226272444,"author":{"id":4093757289971380,"authorId":4093757289971380,"authorIdStr":"4093757289971380","name":"new_money","avatar":"https://static.tigerbbs.com/11c53e8b0bc90836e57b9dbd4236a68a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>I see, good</p></body></html>","htmlText":"<html><head></head><body><p>I see, good</p></body></html>","text":"I see, good","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/825232679","repostId":1151136903,"repostType":4,"repost":{"id":"1151136903","pubTimestamp":1634225065,"share":"https://www.laohu8.com/m/news/1151136903?lang=&edition=full","pubTime":"2021-10-14 23:24","market":"us","language":"en","title":"Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1151136903","media":"Motley Fool","summary":"New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>An infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.</li>\n <li>Aviptadil is in development for the treatment of respiratory failure related to severe COVID infection.</li>\n <li>The peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>NRx Pharmaceuticals</b>(NASDAQ:NRXP)&nbsp;are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some&nbsp;positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.</p>\n<p><b>So what</b></p>\n<p>This morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2822fcb875474824949ad943caf5b99\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>The number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to&nbsp;market-beating gains&nbsp;for NRx Pharmaceuticals investors.</p>\n<p><b>Now what</b></p>\n<p>Unfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.</p>\n<p>Today's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.</p>\n<p>In place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy NRx Pharmaceuticals Stock Is Jumping Again on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 23:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151136903","content_text":"Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory failure related to severe COVID infection.\nThe peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.\n\nWhat happened\nShares of NRx Pharmaceuticals(NASDAQ:NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.\nSo what\nThis morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.\nIMAGE SOURCE: GETTY IMAGES.\nThe number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.\nNow what\nUnfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.\nToday's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.\nIn place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.","news_type":1},"isVote":1,"tweetType":1,"viewCount":526,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}